Exact Mass: 628.3459

Exact Mass Matches: 628.3459

Found 302 metabolites which its exact mass value is equals to given mass value 628.3459, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Gambogic acid

(2Z)-4-[12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


Isolated from Gamboge resin (exudate of Garcinia morella). Gambogic acid is found in herbs and spices and fruits. Gambogic acid is found in fruits. Gambogic acid is isolated from Gamboge resin (exudate of Garcinia morella). Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM. Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.

   

Lopinavir

N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide

C37H48N4O5 (628.3625)


Lopinavir is only found in individuals that have used or taken this drug. It is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles. D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors CONFIDENCE standard compound; INTERNAL_ID 2288 Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

BQ 485

N-(N-(N-((Hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-D-tryptophan

C35H44N6O5 (628.3373)


   

(3S,5R,6R,6'S)-6,7-Didehydro-5,6-dihydro-3,5,6'-trihydroxy-13,14,20-trinor-3'-oxo-beta,epsilon-caroten-19',11'-olide 3-acetate

3-Hydroxy-4-[(3E,5E,7E,9E)-10-{[(2Z)-4-[(e)-2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)ethenyl]-5-oxo-2,5-dihydrofuran-2-ylidene]methyl}-3-methylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetic acid

C39H48O7 (628.34)


(3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate is found in mollusks. (3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate is a constituent of the oyster Crassostrea gigas. Constituent of the oyster Crassostrea gigas. (3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate is found in mollusks.

   

LysoPI(20:0/0:0)

[(2R)-2-hydroxy-3-(icosanoyloxy)propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C29H57O12P (628.3587)


LysoPI(20:0/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(20:0/0:0), in particular, consists of one chain of arachidic acid at the C-1 position.

   

N-(N-(N-((Hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-D-tryptophan

2-({2-[(2-{[(azepan-1-yl)(hydroxy)methylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene}amino)-3-(1H-indol-3-yl)propanoate

C35H44N6O5 (628.3373)


   

Cholylglycyltyrosine

3-(4-hydroxyphenyl)-2-[2-(4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)acetamido]propanoic acid

C35H52N2O8 (628.3723)


   

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-(decanoyloxy)-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-(decanoyloxy)-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

[(2R)-2-(decanoyloxy)-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-3-(decanoyloxy)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

C33H57O9P (628.374)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-3-(decanoyloxy)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-3-(decanoyloxy)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.374)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Gambogic_acid

2-Butenoic acid, 2-methyl-4-[3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-, [1R-[1.alpha.,1(Z),3a.beta.,5.alpha.,11.beta.,14aS*]]-

C38H44O8 (628.3036)


beta-Guttiferin is a natural product found in Garcinia hanburyi with data available. Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM. Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.

   

gambogellic acid

(E)-4-[(2S,8R,19S)-14-Hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-enyl)-16,20-dioxo-11-prop-1-en-2-yl-3,7,22-trioxaheptacyclo[17.4.1.18,12.02,17.02,21.04,15.06,13]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

Gambogellic

(E)-4-[14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-enyl)-16,20-dioxo-11-prop-1-en-2-yl-3,7,22-trioxaheptacyclo[17.4.1.18,12.02,17.02,21.04,15.06,13]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   
   
   

2-N-(1-Deoxy-1-beta-D-fructopyranosyl)cephaeline

2-N-(1-Deoxy-1-beta-D-fructopyranosyl)cephaeline

C34H48N2O9 (628.336)


   

Gambogefic acid

(-)-Gambogefic acid

C38H44O8 (628.3036)


   

2-N-(1-deoxy-1-beta-D-fructopyranosyl)neocephaeline

2-N-(1-deoxy-1-beta-D-fructopyranosyl)neocephaeline

C34H48N2O9 (628.336)


   

chisonimbolinin E

chisonimbolinin E

C35H48O10 (628.3247)


   

Epigambogic acid

(-)-Epigambogic acid

C38H44O8 (628.3036)


   

Epiisogambogic acid

Epiisogambogic acid

C38H44O8 (628.3036)


   

(2R,2R,3S,3S)-2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

(2R,2R,3S,3S)-2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3764)


   

onchitriol II D|Onchitriol IID

onchitriol II D|Onchitriol IID

C36H52O9 (628.3611)


   

(22S,25S)-1alpha,2beta,3alpha,5alpha-tetrahydroxy-furo-spirostane-26-yl O-beta-D-glucopyranoside|tupistroside C

(22S,25S)-1alpha,2beta,3alpha,5alpha-tetrahydroxy-furo-spirostane-26-yl O-beta-D-glucopyranoside|tupistroside C

C32H52O12 (628.3459)


   

3-(2,16,19,20-tetradehydro-17-oxocuran-10-yl)vobasan-17-oic acid methyl ester|vobatricine

3-(2,16,19,20-tetradehydro-17-oxocuran-10-yl)vobasan-17-oic acid methyl ester|vobatricine

C40H44N4O3 (628.3413)


   

milbemycins VM48641

milbemycins VM48641

C36H52O9 (628.3611)


   

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

C36H52O9 (628.3611)


   

7-isoprenylmorellic acid

7-isoprenylmorellic acid

C38H44O8 (628.3036)


   

De-O-methyltenuicausine

De-O-methyltenuicausine

C40H44N4O3 (628.3413)


   

sapinsignoid A

sapinsignoid A

C36H52O9 (628.3611)


   

(25R)-5beta-furostane-1beta,3beta,11alpha,22alpha,26-pentaol 26-O-beta-D-glucopyranoside|caucasicoside F

(25R)-5beta-furostane-1beta,3beta,11alpha,22alpha,26-pentaol 26-O-beta-D-glucopyranoside|caucasicoside F

C33H56O11 (628.3822)


   
   

obtusinone D

obtusinone D

C40H52O6 (628.3764)


   

obtusinone E

obtusinone E

C40H52O6 (628.3764)


   
   

salvialeriafone

salvialeriafone

C39H48O7 (628.34)


   

(4aS,10aS)-6-{2-[2-(acetyloxy)-3-hydroxy-1-oxo-3-phenylpropyl]-3-hydroxy-5-methoxyphenoxy}-2,3,4,4a,10,10a-hexahydro-1,1,4a-trimethyl-7-(1-methylethyl)phenanthren-9(1H)-one|salicassin

(4aS,10aS)-6-{2-[2-(acetyloxy)-3-hydroxy-1-oxo-3-phenylpropyl]-3-hydroxy-5-methoxyphenoxy}-2,3,4,4a,10,10a-hexahydro-1,1,4a-trimethyl-7-(1-methylethyl)phenanthren-9(1H)-one|salicassin

C38H44O8 (628.3036)


   

onchitriol I A|Onchitriol IA

onchitriol I A|Onchitriol IA

C36H52O9 (628.3611)


   

anatolioside A

anatolioside A

C32H52O12 (628.3459)


   

5beta-cholestane-3alpha,7alpha,12alpha,23,25-pentol-23-glucuronide

5beta-cholestane-3alpha,7alpha,12alpha,23,25-pentol-23-glucuronide

C33H56O11 (628.3822)


   
   

(2R,3S,2R,3S)-2,3,2,3-tetrahydroxy-beta,beta-carotene-4,4-dione|2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione|2,3,2,3-Tetrahydroxy-beta,beta-caroten-4,4-dion

(2R,3S,2R,3S)-2,3,2,3-tetrahydroxy-beta,beta-carotene-4,4-dione|2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione|2,3,2,3-Tetrahydroxy-beta,beta-caroten-4,4-dion

C40H52O6 (628.3764)


   

Leu Ile Val Asp Arg

Leu Ile Val Asp Arg

C28H52N8O8 (628.3908)


   

Leu Ala Arg Glu Leu

Leu Ala Arg Glu Leu

C28H52N8O8 (628.3908)


   

Pro Glu Glu Leu Lys

Pro Glu Glu Leu Lys

C28H48N6O10 (628.3432)


   

Lopinavir

Lopinavir (ABT-378)

C37H48N4O5 (628.3625)


D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

gambogic acid

(E)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM. Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.

   

GAMBOGIC ACID_46.9\\%

GAMBOGIC ACID_46.9\\%

C38H44O8 (628.3036)


   

GAMBOGIC ACID_major

GAMBOGIC ACID_major

C38H44O8 (628.3036)


   

GAMBOGIC ACID_76.6\\%

GAMBOGIC ACID_76.6\\%

C38H44O8 (628.3036)


   

Lys Arg Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3333)


   

Lys Tyr Arg Tyr

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]pentanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3333)


   

Lys Tyr Tyr Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]pentanoic acid

C30H44N8O7 (628.3333)


   

Gln Arg Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C29H40N8O8 (628.2969)


   

Gln Tyr Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C29H40N8O8 (628.2969)


   

Gln Tyr Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C29H40N8O8 (628.2969)


   

Arg Lys Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3333)


   

Arg Gln Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C29H40N8O8 (628.2969)


   

Arg Tyr Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3333)


   

Arg Tyr Gln Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C29H40N8O8 (628.2969)


   

Arg Tyr Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C30H44N8O7 (628.3333)


   

Arg Tyr Tyr Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanoic acid

C29H40N8O8 (628.2969)


   

Tyr Lys Arg Tyr

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3333)


   

Tyr Lys Tyr Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C30H44N8O7 (628.3333)


   

Tyr Gln Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C29H40N8O8 (628.2969)


   

Tyr Gln Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C29H40N8O8 (628.2969)


   

Tyr Arg Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N8O7 (628.3333)


   

Tyr Arg Gln Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C29H40N8O8 (628.2969)


   

Tyr Arg Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C30H44N8O7 (628.3333)


   

Tyr Arg Tyr Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanoic acid

C29H40N8O8 (628.2969)


   

Tyr Tyr Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]-5-carbamimidamidopentanoic acid

C30H44N8O7 (628.3333)


   

Tyr Tyr Gln Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanoic acid

C29H40N8O8 (628.2969)


   

Tyr Tyr Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]hexanoic acid

C30H44N8O7 (628.3333)


   

Tyr Tyr Arg Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanoic acid

C29H40N8O8 (628.2969)


   

RLLNN

Arg-Leu-Leu-Asn-Asn

C26H48N10O8 (628.3656)


   

PI(20:0/0:0)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587)


   

(3S,5R,6R,6'S)-6,7-Didehydro-5,6-dihydro-3,5,6'-trihydroxy-13,14,20-trinor-3'-oxo-beta,epsilon-caroten-19',11'-olide 3-acetate

3-hydroxy-4-[(3E,5E,7E,9E)-11-[(2Z)-4-[(E)-2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)ethenyl]-5-oxo-2,5-dihydrofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C39H48O7 (628.34)


   
   

LPI 20:0

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587)


   

Astaxanthin-5,6-peroxide

5,6-Peroxy-3,3-dihydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3764)


   

Astaxanthin-5,8-peroxide

5,8-Peroxy-3,3-dihydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3764)


   

2,2-Dihydroxyastaxanthin

(2R,3S,2R,3S)-2,3,2,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3764)


   

(3S,5R,6S)-3-ethanoyloxy-5,6-dihydroxy-5,67,8-tetradehydro-11,19-olide-20-nor-beta,epsilon-caroten-3-one

(3S,5R,6S)-3-ethanoyloxy-5,6-dihydroxy-5,67,8-tetradehydro-11,19-olide-20-nor-beta,epsilon-caroten-3-one

C39H48O7 (628.34)


   

β-​Alanine, N-​[[2-​[[[4-​[[[(hexyloxy)​carbonyl]​amino]​carbonyl]​phenyl]​amino]​methyl]​-​1-​methyl-​1H-​benzimidazol-​5-​yl]​carbonyl]​-​N-​2-​pyridinyl-​, ethyl ester

β-​Alanine, N-​[[2-​[[[4-​[[[(hexyloxy)​carbonyl]​amino]​carbonyl]​phenyl]​amino]​methyl]​-​1-​methyl-​1H-​benzimidazol-​5-​yl]​carbonyl]​-​N-​2-​pyridinyl-​, ethyl ester

C34H40N6O6 (628.3009)


   

7-amino-6-[(2-aminoacetyl)amino]-2-[[4-carboxy-4-[2-(dodecanoylamino)propanoylamino]butanoyl]amino]-7-oxoheptanoic acid

7-amino-6-[(2-aminoacetyl)amino]-2-[[4-carboxy-4-[2-(dodecanoylamino)propanoylamino]butanoyl]amino]-7-oxoheptanoic acid

C29H52N6O9 (628.3796)


   

Levalbuterol tartrate

Levalbuterol tartrate

C30H48N2O12 (628.3207)


C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

   

Repaglinide Acyl-β-D-glucuronide

Repaglinide Acyl-β-D-glucuronide

C33H44N2O10 (628.2996)


   

Cholylglycyltyrosine

Cholylglycyltyrosine

C35H52N2O8 (628.3723)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C33H57O9P (628.374)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C33H57O9P (628.374)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

C33H57O9P (628.374)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

C33H57O9P (628.374)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C33H57O9P (628.374)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C33H57O9P (628.374)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C33H57O9P (628.374)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

C33H57O9P (628.374)


   

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C33H57O9P (628.374)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

C33H57O9P (628.374)


   

LysoPI(20:0/0:0)

LysoPI(20:0/0:0)

C29H57O12P (628.3587)


   
   

Perhydroazepino-N-carbonyl-L-Leu-D-Trp-D-Trp

Perhydroazepino-N-carbonyl-L-Leu-D-Trp-D-Trp

C35H44N6O5 (628.3373)


   

N-[[(3S,9R,10R)-16-[[anilino(oxo)methyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylcarbamic acid 2-methoxyethyl ester

N-[[(3S,9R,10R)-16-[[anilino(oxo)methyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylcarbamic acid 2-methoxyethyl ester

C33H48N4O8 (628.3472)


   

Dabigatran etexilate cation

Dabigatran etexilate cation

C34H42N7O5+ (628.3247)


   

(3S)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide

(3S)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-N-[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide

C36H44N4O4S (628.3083)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3625)


   

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3625)


   

[(3R)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-[4-(phenylmethyl)-1-piperazinyl]methanone

[(3R)-2-tert-butylsulfinyl-3-(2-hydroxyethyl)-4-[3-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl]-[4-(phenylmethyl)-1-piperazinyl]methanone

C36H44N4O4S (628.3083)


   
   

3-Didehydro-5-dehydroxyhydratoperidinin

3-Didehydro-5-dehydroxyhydratoperidinin

C39H48O7 (628.34)


   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

C29H57O12P (628.3587)


   

Smgdg O-9:0_11:0

Smgdg O-9:0_11:0

C29H56O12S (628.3492)


   

Smgdg O-18:0_2:0

Smgdg O-18:0_2:0

C29H56O12S (628.3492)


   

Smgdg O-8:0_12:0

Smgdg O-8:0_12:0

C29H56O12S (628.3492)


   

Smgdg O-17:0_3:0

Smgdg O-17:0_3:0

C29H56O12S (628.3492)


   

Smgdg O-12:0_8:0

Smgdg O-12:0_8:0

C29H56O12S (628.3492)


   

Smgdg O-15:0_5:0

Smgdg O-15:0_5:0

C29H56O12S (628.3492)


   

Smgdg O-11:0_9:0

Smgdg O-11:0_9:0

C29H56O12S (628.3492)


   

Smgdg O-13:0_7:0

Smgdg O-13:0_7:0

C29H56O12S (628.3492)


   

Smgdg O-16:0_4:0

Smgdg O-16:0_4:0

C29H56O12S (628.3492)


   

Smgdg O-14:0_6:0

Smgdg O-14:0_6:0

C29H56O12S (628.3492)


   

Smgdg O-10:0_10:0

Smgdg O-10:0_10:0

C29H56O12S (628.3492)


   

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

C29H57O12P (628.3587)


   

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C32H53O10P (628.3376)


   

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C32H53O10P (628.3376)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C32H53O10P (628.3376)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] hexadecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] hexadecanoate

C28H53O13P (628.3224)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C32H53O10P (628.3376)


   

[1-Hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] tridecanoate

[1-Hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] tridecanoate

C28H53O13P (628.3224)


   

[1-Heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

[1-Heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

C28H53O13P (628.3224)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] decanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] decanoate

C28H53O13P (628.3224)


   

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C32H53O10P (628.3376)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] tetradecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] tetradecanoate

C28H53O13P (628.3224)


   

[1-Butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] pentadecanoate

[1-Butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] pentadecanoate

C28H53O13P (628.3224)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] undecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] undecanoate

C28H53O13P (628.3224)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C32H53O10P (628.3376)


   

[1-Acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] heptadecanoate

[1-Acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] heptadecanoate

C28H53O13P (628.3224)


   

[(1R,3S)-3-hydroxy-4-[(3E,5E,7E,9E,11Z)-11-[4-[(E)-2-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate

[(1R,3S)-3-hydroxy-4-[(3E,5E,7E,9E,11Z)-11-[4-[(E)-2-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate

C39H48O7 (628.34)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C35H49O8P (628.3165)


   

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C32H53O10P (628.3376)


   

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C32H53O10P (628.3376)


   

[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C32H53O10P (628.3376)


   

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3E)-3-ethylidene-2-(2-hydroxyethyl)-2,4-dihydro-1H-indolo[2,3-a]quinolizin-7-yl]propanoate

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3E)-3-ethylidene-2-(2-hydroxyethyl)-2,4-dihydro-1H-indolo[2,3-a]quinolizin-7-yl]propanoate

C40H44N4O3 (628.3413)


   

(3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate

(3S,5R,6R,6S)-6,7-Didehydro-5,6-dihydro-3,5,6-trihydroxy-13,14,20-trinor-3-oxo-beta,epsilon-caroten-19,11-olide 3-acetate

C39H48O7 (628.34)


   

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587)


   

(-)-Gambogic Acid

(-)-Gambogic Acid

C38H44O8 (628.3036)


A natural product found in Garcinia hanburyi.

   
   
   
   
   

PA O-30:5;O2

PA O-30:5;O2

C33H57O9P (628.374)


   

PA P-18:1/11:4;O3

PA P-18:1/11:4;O3

C32H53O10P (628.3376)


   

PA P-18:1/12:3;O2

PA P-18:1/12:3;O2

C33H57O9P (628.374)


   

PA 16:1/13:4;O2

PA 16:1/13:4;O2

C32H53O10P (628.3376)


   

PA 18:1/12:3;O

PA 18:1/12:3;O

C33H57O9P (628.374)


   
   
   
   
   

PA 22:1/8:3;O

PA 22:1/8:3;O

C33H57O9P (628.374)


   
   
   
   
   
   

PG P-18:1/8:4;O

PG P-18:1/8:4;O

C32H53O10P (628.3376)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

PEth 28:4;O

PEth 28:4;O

C33H57O9P (628.374)


   
   

ST 25:2;O7;GlcA

ST 25:2;O7;GlcA

C31H48O13 (628.3095)


   

ST 26:1;O6;GlcA

ST 26:1;O6;GlcA

C32H52O12 (628.3459)


   

ST 27:0;O5;GlcA

ST 27:0;O5;GlcA

C33H56O11 (628.3822)


   

ST 29:6;O4;GlcA

ST 29:6;O4;GlcA

C35H48O10 (628.3247)


   

ST 25:3;O8;Hex

ST 25:3;O8;Hex

C31H48O13 (628.3095)


   

ST 26:2;O7;Hex

ST 26:2;O7;Hex

C32H52O12 (628.3459)


   

ST 27:1;O6;Hex

ST 27:1;O6;Hex

C33H56O11 (628.3822)


   

ST 29:7;O5;Hex

ST 29:7;O5;Hex

C35H48O10 (628.3247)


   

(2z)-4-[(1s,2s,9r,14r,21s,23r)-16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

(2z)-4-[(1s,2s,9r,14r,21s,23r)-16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

(2e)-4-[(2s,8r,19s)-14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

(2e)-4-[(2s,8r,19s)-14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

4-[12-hydroxy-8,8,21,21-tetramethyl-5,17-bis(3-methylbut-2-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

4-[12-hydroxy-8,8,21,21-tetramethyl-5,17-bis(3-methylbut-2-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(2e)-4-[(1s,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

(2e)-4-[(1s,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

2-hydroxy-3-({7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoyl}oxy)propyl 7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoate

2-hydroxy-3-({7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoyl}oxy)propyl 7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoate

C39H48O7 (628.34)


   

(2z)-4-[(1r,2r,17r,19s)-12-hydroxy-8,8,21,21-tetramethyl-5,17-bis(3-methylbut-2-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

(2z)-4-[(1r,2r,17r,19s)-12-hydroxy-8,8,21,21-tetramethyl-5,17-bis(3-methylbut-2-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611)


   

(2s,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]oxy}-2-methyloxane-3,4,5-triol

(2s,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]oxy}-2-methyloxane-3,4,5-triol

C34H48N2O9 (628.336)


   

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

C34H48N2O9 (628.336)


   

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3459)


   

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611)


   

n-{2-[({11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methoxy)carbonyl]phenyl}ethanimidic acid

n-{2-[({11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methoxy)carbonyl]phenyl}ethanimidic acid

C34H48N2O9 (628.336)


   

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3r)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3r)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

ajacine

NA

C34H48N2O9 (628.336)


{"Ingredient_id": "HBIN014949","Ingredient_name": "ajacine","Alias": "NA","Ingredient_formula": "C34H48N2O9","Ingredient_Smile": "CCN1CC2(CCC(C34C2C(C(C31)(C5(CC(C6CC4C5C6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7NC(=O)C","Ingredient_weight": "628.8 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "781","TCMSP_id": "NA","TCM_ID_id": "7100;12307;12308","PubChem_id": "101667972","DrugBank_id": "NA"}

   

allogambogic acid

NA

C38H44O8 (628.3036)


{"Ingredient_id": "HBIN015220","Ingredient_name": "allogambogic acid","Alias": "NA","Ingredient_formula": "C38H44O8","Ingredient_Smile": "CC(=CCCC1(C=CC2=C(C(=C3C(=C2O1)C(=O)C4=CC5CC6C4(O3)C(C5=O)(OC6(C)C)CC=C(C)C(=O)O)CC=C(C)C)O)C)C","Ingredient_weight": "628.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "23602","TCMSP_id": "NA","TCM_ID_id": "7006","PubChem_id": "6444544","DrugBank_id": "NA"}

   

(2e)-4-[(8s)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

(2e)-4-[(8s)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(2z)-4-[(1s,2s,8s,11s,12s,19s,21r)-14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

(2z)-4-[(1s,2s,8s,11s,12s,19s,21r)-14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 6-hydroxy-2,6-dimethylocta-2,7-dienoate

6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3459)


   

(1s,2s,4s,6r,8s,11s,12r,13s,16s,17s,19r,20s)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1s,2s,4s,6r,8s,11s,12r,13s,16s,17s,19r,20s)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

n-[2-({[(1r,2r,3r,4s,5r,6s,8r,9r,10r,13r,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1r,2r,3r,4s,5r,6s,8r,9r,10r,13r,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C34H48N2O9 (628.336)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-[(3r)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-[(3r)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

4-[16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

4-[16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

4-[(1r,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

4-[(1r,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6r)-6-hydroxytetradeca-2,4-dienoate

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6r)-6-hydroxytetradeca-2,4-dienoate

C36H52O9 (628.3611)


   

ethyl (1r,2s,5s)-16-[(2z)-3-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-4-hydroxybut-2-en-1-yl]-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

ethyl (1r,2s,5s)-16-[(2z)-3-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-4-hydroxybut-2-en-1-yl]-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C39H48O7 (628.34)


   

(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e)-11-[(2z)-4-[(1e)-2-[(1s)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e)-11-[(2z)-4-[(1e)-2-[(1s)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene]-3,5,5-trimethylcyclohexyl acetate

C39H48O7 (628.34)


   

4-[12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

4-[12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

3-hydroxy-4-(11-{4-[2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)ethenyl]-5-oxofuran-2-ylidene}-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate

3-hydroxy-4-(11-{4-[2-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)ethenyl]-5-oxofuran-2-ylidene}-3,10-dimethylundeca-1,3,5,7,9-pentaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate

C39H48O7 (628.34)


   

(2r,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-8-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

(2r,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-8-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

C34H48N2O9 (628.336)


   

3-[18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

3-[18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

C40H52O6 (628.3764)


   

3-[(9e,11e,13e,15e,17e)-18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

3-[(9e,11e,13e,15e,17e)-18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

C40H52O6 (628.3764)


   

1,5,12,16,24,28-hexahydroxy-1,6,12,17,24,29-hexaazacyclopentatriaconta-5,16,28-triene-2,13,25-trione

1,5,12,16,24,28-hexahydroxy-1,6,12,17,24,29-hexaazacyclopentatriaconta-5,16,28-triene-2,13,25-trione

C29H52N6O9 (628.3796)


   

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C34H48N2O9 (628.336)


   

2-{2-[(1r,2s,5s)-10,14-dihydroxy-5-(methoxycarbonyl)-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaen-16-yl]ethylidene}-6,10-dimethylundeca-5,9-dienoic acid

2-{2-[(1r,2s,5s)-10,14-dihydroxy-5-(methoxycarbonyl)-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaen-16-yl]ethylidene}-6,10-dimethylundeca-5,9-dienoic acid

C38H44O8 (628.3036)


   

(5r,6s)-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s,5r)-4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

(5r,6s)-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s,5r)-4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

C40H52O6 (628.3764)


   

(2z)-4-[(1s,2s,8s,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

(2z)-4-[(1s,2s,8s,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(2r,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

(2r,3s,4r,5r)-2-{[(1r)-1-{[(2r,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]methyl}-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

C34H48N2O9 (628.336)


   

1-hydroxy-3-({7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoyl}oxy)propan-2-yl 7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoate

1-hydroxy-3-({7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoyl}oxy)propan-2-yl 7-[3-(nona-4,6-dien-1-yl)oxiran-2-yl]hepta-4,6-diynoate

C39H48O7 (628.34)


   

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3s)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3s)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-2-methylbut-2-enoate

C35H48O10 (628.3247)


   

(3s,6s,9s,12s,20as)-12-benzyl-1,4,7,10,13-pentahydroxy-6-[(1r)-1-hydroxyethyl]-3,9-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(3s,6s,9s,12s,20as)-12-benzyl-1,4,7,10,13-pentahydroxy-6-[(1r)-1-hydroxyethyl]-3,9-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C32H48N6O7 (628.3584)


   

2-hydroxy-3-({7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoyl}oxy)propyl 7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoate

2-hydroxy-3-({7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoyl}oxy)propyl 7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoate

C39H48O7 (628.34)


   

4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl 2-methylbut-2-enoate

4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl 2-methylbut-2-enoate

C35H48O10 (628.3247)


   

methyl (1s,2r,10r,17s,19s,20r,22s,23s,27r,39s)-17,22-diethyl-21-oxa-3,13,24,34-tetraazadodecacyclo[20.15.1.1¹⁰,¹³.0¹,²⁴.0²,²⁷.0³,²⁰.0⁴,⁹.0¹⁰,²⁰.0¹⁹,²³.0²⁷,³⁵.0²⁸,³³.0¹⁷,³⁹]nonatriaconta-4,6,8,15,28,30,32,35-octaene-36-carboxylate

methyl (1s,2r,10r,17s,19s,20r,22s,23s,27r,39s)-17,22-diethyl-21-oxa-3,13,24,34-tetraazadodecacyclo[20.15.1.1¹⁰,¹³.0¹,²⁴.0²,²⁷.0³,²⁰.0⁴,⁹.0¹⁰,²⁰.0¹⁹,²³.0²⁷,³⁵.0²⁸,³³.0¹⁷,³⁹]nonatriaconta-4,6,8,15,28,30,32,35-octaene-36-carboxylate

C40H44N4O3 (628.3413)


   

4-[14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

4-[14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(2r,3r,4r,5r,6e,8s)-5-(acetyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4r,5r,6e,8s)-5-(acetyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611)


   

(2s)-1-hydroxy-3-({7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoyl}oxy)propan-2-yl 7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoate

(2s)-1-hydroxy-3-({7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoyl}oxy)propan-2-yl 7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoate

C39H48O7 (628.34)


   

17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

17-(acetyloxy)-4-ethoxy-19-hydroxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

C35H48O10 (628.3247)


   

6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3459)


   

(2e)-4-[(1s,2s,9s,14r,21s,23r)-16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

(2e)-4-[(1s,2s,9s,14r,21s,23r)-16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C34H48N2O9 (628.336)


   

n-[2-({[(1r,2r,3r,4s,5r,6s,8r,9r,10r,13r,16s,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1r,2r,3r,4s,5r,6s,8r,9r,10r,13r,16s,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C34H48N2O9 (628.336)


   

(2e)-4-[(1s,2s,8s,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

(2e)-4-[(1s,2s,8s,17s,19r)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

(2z)-4-[16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

(2z)-4-[16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

methyl (1s,12s,14r,15z,18s)-15-ethylidene-12-[(11s,12z,17s)-12-ethylidene-10-formyl-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6,9-tetraen-4-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12s,14r,15z,18s)-15-ethylidene-12-[(11s,12z,17s)-12-ethylidene-10-formyl-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6,9-tetraen-4-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C40H44N4O3 (628.3413)


   

(2e)-4-[(1s,2s,8r,11s,12r,19s,21r)-14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

(2e)-4-[(1s,2s,8r,11s,12r,19s,21r)-14-hydroxy-8,23,23-trimethyl-5-(3-methylbut-2-en-1-yl)-16,20-dioxo-11-(prop-1-en-2-yl)-3,7,22-trioxaheptacyclo[17.4.1.1⁸,¹².0²,¹⁷.0²,²¹.0⁴,¹⁵.0⁶,¹³]pentacosa-4(15),5,13,17-tetraen-21-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)


   

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]oxy}-2-methyloxane-3,4,5-triol

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-6-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]oxy}-2-methyloxane-3,4,5-triol

C34H48N2O9 (628.336)


   

ethyl (1s,2r,5r)-16-[(2z)-3-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-4-hydroxybut-2-en-1-yl]-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

ethyl (1s,2r,5r)-16-[(2z)-3-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-4-hydroxybut-2-en-1-yl]-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C39H48O7 (628.34)


   

1-hydroxy-3-({7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoyl}oxy)propan-2-yl 7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoate

1-hydroxy-3-({7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoyl}oxy)propan-2-yl 7-[(2s,3s)-3-[(4z,6z)-nona-4,6-dien-1-yl]oxiran-2-yl]hepta-4,6-diynoate

C39H48O7 (628.34)


   

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6s)-6-hydroxytetradeca-2,4-dienoate

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6s)-6-hydroxytetradeca-2,4-dienoate

C36H52O9 (628.3611)


   

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-8-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

2-{[1-({3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-8-hydroxy-7-methoxy-3,4-dihydro-1h-isoquinolin-2-yl]methyl}oxane-2,3,4,5-tetrol

C34H48N2O9 (628.336)


   

2-{2-[(1s,2r,5r)-10,14-dihydroxy-5-(methoxycarbonyl)-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaen-16-yl]ethylidene}-6,10-dimethylundeca-5,9-dienoic acid

2-{2-[(1s,2r,5r)-10,14-dihydroxy-5-(methoxycarbonyl)-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaen-16-yl]ethylidene}-6,10-dimethylundeca-5,9-dienoic acid

C38H44O8 (628.3036)


   

(2z)-4-[(1s,2s,21s,23r)-16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

(2z)-4-[(1s,2s,21s,23r)-16-hydroxy-8,8,12,25,25-pentamethyl-5-(3-methylbut-2-en-1-yl)-18,22-dioxo-3,7,24-trioxaheptacyclo[19.4.1.0²,¹⁹.0²,²³.0⁴,¹⁷.0⁶,¹⁵.0⁹,¹⁴]hexacosa-4,6(15),12,16,19-pentaen-23-yl]-2-methylbut-2-enoic acid

C38H44O8 (628.3036)